NCT00835354View on ClinicalTrials.gov

Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

May 31, 2004

Study Completion Date

May 31, 2004

Conditions
Healthy
Interventions
DRUG

Cefprozil for oral suspension 250 mg/5 mL

1 x 250 mg/5 mL, single-dose fasting

DRUG

CEFZIL® for Oral Suspension 250 mg/5mL

1 x 250 mg/5 mL, single-dose fasting

Trial Locations (2)

63301

Gateway Medical Research, Inc., Saint Charles

77099

Bioassay Laboratory, Inc., Houston

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT00835354 - Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting | Biotech Hunter | Biotech Hunter